RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Halozyme Therapeutics Stock

Halozyme Therapeutics ROA 2024

Halozyme Therapeutics ROA

0.16

Ticker

HALO

ISIN

US40637H1095

WKN

A0DLHS

In 2024, Halozyme Therapeutics's return on assets (ROA) was 0.16, a 48.03% increase from the 0.11 ROA in the previous year.

Halozyme Therapeutics Aktienanalyse

What does Halozyme Therapeutics do?

Halozyme Therapeutics Inc is a biotechnology company based in San Diego, California, specializing in the development of therapies for cancer and rare diseases. The company was founded in 1998 and has been listed on the NASDAQ since 2004. The business model of Halozyme is based on the use of the enzyme hyaluronidase, which helps distribute medications more quickly and effectively in the body. By using hyaluronidase, the absorption of medications can be improved, increasing their effectiveness and improving patient treatment. The company operates in three different areas: the first area is the development of its own therapies based on the use of hyaluronidase. Halozyme has several medications in the pipeline, including a therapy for pancreatic cancer and a treatment for muscular dystrophy. The second area is partnering with other pharmaceutical companies to enable faster absorption of their medications through the use of hyaluronidase. Halozyme has entered into over 30 partnerships with companies such as Pfizer, Roche, and Janssen. The third area is the development of diagnostic tools based on the analysis of protein-protein interactions. This technology is intended to accelerate the drug development process and support the selection of the most promising candidates. An example of a product developed by Halozyme in collaboration with a partner company is Herceptin SC (subcutaneous). Herceptin is a medication for the treatment of breast cancer that is typically administered intravenously. However, by adding hyaluronidase, the medication can also be administered subcutaneously, reducing treatment duration and patient burden. Halozyme aims to develop innovative therapies and accelerate the drug development process. By using hyaluronidase and partnering with other companies, the company can contribute to improving the effectiveness of medications and optimizing treatment outcomes for patients. Halozyme Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Halozyme Therapeutics's Return on Assets (ROA)

Halozyme Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Halozyme Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Halozyme Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Halozyme Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Halozyme Therapeutics stock

What is the Return on Assets (ROA) of Halozyme Therapeutics this year?

The Return on Assets (ROA) of Halozyme Therapeutics is 0.16 undefined this year.

What was the ROA of Halozyme Therapeutics compared to the previous year?

The ROA of Halozyme Therapeutics has increased by 48.03% compared to the previous year.

What consequences do high ROA have for investors of Halozyme Therapeutics?

A high ROA is advantageous for investors of Halozyme Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Halozyme Therapeutics?

A low ROA can be unfavorable for investors of Halozyme Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Halozyme Therapeutics affect the company?

An increase in ROA of Halozyme Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Halozyme Therapeutics impact the company?

A reduction in the ROA of Halozyme Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Halozyme Therapeutics?

Some factors that can influence the ROA of Halozyme Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Halozyme Therapeutics important for investors?

The ROA of Halozyme Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Halozyme Therapeutics take to improve ROA?

To improve ROA, Halozyme Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Halozyme Therapeutics pay?

Over the past 12 months, Halozyme Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Halozyme Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Halozyme Therapeutics?

The current dividend yield of Halozyme Therapeutics is .

When does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Halozyme Therapeutics?

Halozyme Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Halozyme Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Halozyme Therapeutics located?

Halozyme Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Halozyme Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Halozyme Therapeutics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Halozyme Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Halozyme Therapeutics in the year 2023?

In the year 2023, Halozyme Therapeutics distributed 0 USD as dividends.

In which currency does Halozyme Therapeutics pay out the dividend?

The dividends of Halozyme Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Halozyme Therapeutics

Our stock analysis for Halozyme Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Halozyme Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.